Japan Chemical Research And Asuka Pharma To Develop New Biotech Drug To Treat MPS
This article was originally published in PharmAsia News
Japan Chemical Research and Tokyo-based Asuka Pharmaceuticals will jointly develop and market a drug to treat mucopolysaccharidosis (MPS), a type of genetic liposomal storage disorder. The biotech drug uses genetic modification technology, and it was cultured under serum-free conditions. By not using cow blood serum, the companies say it is more cost efficient and eliminates the risk of BSE infections. Asuka and Japan Chemical hope to enter the drug into clinic trials soon. (Click here for more - may require subscription
You may also be interested in...
The company said its own calculations suggest a mid-November readout could yield a positive result, keeping it on track for an EUA before the end of 2020.
With COVID-19 continuing to wreak havoc in the EU just as throughout the globe, the European Commission is proposing new measures that will impact antigen test availability and use
Amgen’s management took a deep dive into biosimilar market dynamics during the company’s third-quarter earnings call, as the California-based biotech continued to enjoy success for biosimilars in the US and Europe.